Ying Y Zhao1, Reena Mehra2. 1. Sleep Care Solutions, 1835 Yonge Street, Suite 303, Toronto, Ontario, M4S 1X8, Canada. yingzhao@mail.harvard.edu. 2. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Abstract
PURPOSE OF REVIEW: Sleep-disordered breathing (SDB) is highly prevalent in heart failure (HF) and may confer significant stress to the cardiovascular system and increases the risk for future cardiovascular events. The present review will provide updates on the current understanding of the relationship of SDB and common HF biomarkers and the effect of positive airway pressure therapy on these biomarkers, with particular emphasis in patients with coexisting SDB and HF. RECENT FINDINGS: Prior studies have examined the relationship between HF biomarkers and SDB, and the effect of SDB treatment on these biomarkers, with less data available in the context of coexisting SDB and HF. Overall, however, the association of SDB and circulating biomarkers has been inconsistent. Further research is needed to elucidate the relationship between biomarkers and SDB in HF, to evaluate the clinical utility of biomarkers over standard methods in large, prospective studies and also to assess the impact of treatment of SDB on these biomarkers in HF via interventional studies.
PURPOSE OF REVIEW: Sleep-disordered breathing (SDB) is highly prevalent in heart failure (HF) and may confer significant stress to the cardiovascular system and increases the risk for future cardiovascular events. The present review will provide updates on the current understanding of the relationship of SDB and common HF biomarkers and the effect of positive airway pressure therapy on these biomarkers, with particular emphasis in patients with coexisting SDB and HF. RECENT FINDINGS: Prior studies have examined the relationship between HF biomarkers and SDB, and the effect of SDB treatment on these biomarkers, with less data available in the context of coexisting SDB and HF. Overall, however, the association of SDB and circulating biomarkers has been inconsistent. Further research is needed to elucidate the relationship between biomarkers and SDB in HF, to evaluate the clinical utility of biomarkers over standard methods in large, prospective studies and also to assess the impact of treatment of SDB on these biomarkers in HF via interventional studies.
Authors: Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger Journal: JAMA Date: 2010-11-15 Impact factor: 56.272
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: Carmen Carmona-Bernal; Esther Quintana-Gallego; Manuel Villa-Gil; Angeles Sánchez-Armengol; Angel Martínez-Martínez; Francisco Capote Journal: Chest Date: 2005-05 Impact factor: 9.410
Authors: Vishesh K Kapur; Dennis H Auckley; Susmita Chowdhuri; David C Kuhlmann; Reena Mehra; Kannan Ramar; Christopher G Harrod Journal: J Clin Sleep Med Date: 2017-03-15 Impact factor: 4.062
Authors: Apoor S Gami; Anna Svatikova; Robert Wolk; Eric J Olson; Carolyn J Duenwald; Allan S Jaffe; Virend K Somers Journal: Chest Date: 2004-06 Impact factor: 9.410
Authors: Ian Ford; Anoop S V Shah; Ruiqi Zhang; David A McAllister; Fiona E Strachan; Muriel Caslake; David E Newby; Chris J Packard; Nicholas L Mills Journal: J Am Coll Cardiol Date: 2016-12-27 Impact factor: 24.094
Authors: Sara V Ochoa; Liliana Otero; Andres Felipe Aristizabal-Pachon; Fernando Hinostroza; Ingrid Carvacho; Yolima P Torres Journal: Front Physiol Date: 2021-12-22 Impact factor: 4.566